We stay ahead of HTA policy and reimbursement trends to help innovator biotechs succeed in European markets.
We stay ahead of HTA policy and reimbursement trends to help innovator biotechs succeed in European markets.
European market access
EU HTAR readiness
Reimbursement due diligence
Payer & HCP research & advisory boards
Value & access function design, optimization & training
We help you answer key business questions such as:
How can we get our product reimbursed in Europe?
What evidence do we need to show value in Europe?
How do we get through European HTA?
How can our drug get a good price in Europe?
What should we invest in Europe – and when?
We help you answer key business questions such as:
How can we get our product
reimbursed in Europe?
What evidence do we need to
show value in Europe?
How do we get through
European HTA?
How can our drug get a
good price in Europe?
What should we invest in
Europe – and when?
We are a unique blend of industry veteran access strategists; value evidence scientists; and creative graphic designers.
We are a unique blend of industry veteran access strategists; value evidence scientists; and creative graphic designers.
Our leadership team has held industry-based executive positions within HEOR/MA
from small biotech to large pharmaceutical companies.
Present in all 4 major European markets
4 principal consultants with over 100 years industry experience
>$12bn in deal value in last 12 months for acquisitions of AESARA-supported products
Experience in rare genetic disorders, infectious diseases, neuroscience, oncology etc.
Our leadership team has held industry-based executive positions within HEOR/MA from small biotech to large pharmaceutical companies.
Present in all 4 major European markets
4 principal consultants with over 100 years industry experience
>$12bn in deal value in last 12 months for acquisitions of AESARA-supported products
Experience in rare genetic disorders, infectious diseases, neuroscience, oncology etc.
© 2023 All Rights Reserved.